Acticor Biotech SAS (EPA:ALACT) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The €11m market-cap company posted a loss in its most recent financial year of €16m and a latest trailing-twelve-month loss of €19m leading to an even wider gap between loss and breakeven. As path to…
Read More…